TGFβ1-IN-1 - ≥99% , CAS No.2348795-14-0

CAS: 2348795-14-0 Cat. No.: T647064 Formula: C₂₂H₂₄N₂O₃ Molecular Weight: 364.44

GRADE & PURITY ≥99%

Storage

Store at 2-8°C,Protected from light,Desiccated

Shipped In

Wet ice

Overview

TGFβ1-IN-1 (compound 42) is a potent, orally active TGF-β1 inhibitor. TGFβ1-IN-1 inhibits the upregulation of TGF-β1-induced fibrosis markers (α-SMA and fibronectin) and can be used in liver fibrosis disease studies.

In Vitro

TGFβ1-IN-1 (compound 42) (0-20 μM, 72 h) inhibits the proliferation of TGF-β1 (5 ng/mL)-treated LX- 2 cells and inhibits LO2 cell viability with an IC 50 of 105 μM. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: HSCs (LX-2) cells Concentration: 20 μM Incubation Time: 24 or 72 hours Result: Showed the survival rate of 77.5% and the inhibition rate of 30.3% for LX-2 cells. Significantly inhibited fibronectin and α-SMA protein expression.

In Vivo

TGFβ1-IN-1 (compound 42) (p.o., 15 or 30 mg/kg, daily, 3weeks) prevents CCl 4 -induced liver injury and fibrosis, inhibits the activation of hepatic stellate cell (HSC) and epithelial-mesenchymal transition (EMT), and improves the immune microenvironment of CCl 4 -induced liver fibrosis as well as CCl 4 -induced systemic toxicity in C57BL/6J mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Liver fibrosis C57BL/6J mice induced by CCl 4 Dosage: 15 or 30 mg/kg Administration: Oral administration; daily; 3 weeks Result: Significantly prevented CCl 4 -induced liver injury and reduced liver weight factor, serum ALT, AST, CHO and TG levels. Significantly improved structural damage and inflammatory cell infiltration in the liver, and reduced collagen deposition in liver tissue. Reduced accumulation of CCl 4 -induced immune cells, such as hepatic macrophages (F4/80 + CD11b + ), Th1 cells (CD69 + CD4 + ), and Th2 cells (CD69 + CD8 + ) so on.

Form:Solid

Specifications

Specifications & Purity

≥99%

Biochemical and Physiological Mechanisms

TGFβ1-IN-1 (compound 42) is a potent, orally active TGF-β1 inhibitor. TGFβ1-IN-1 inhibits the upregulation of TGF-β1-induced fibrosis markers (α-SMA and fibronectin) and can be used in liver fibrosis disease studies.

Storage

Store at 2-8°C,Protected from light,Desiccated

Shipped In

Wet ice

This product requires cold chain shipping. Ground and other economy services are not available.

Purity

≥99%

Names and Identifiers

Canonical Smiles

O=C(NC1CCCC1)C2=CC=CC(NC(/C=C/C3=CC=C(OC)C=C3)=O)=C2

Molecular Weight

364.44

Chemical and Physical Properties

• Solubility: DMSO : 100 mg/mL (274.39 mM; Need ultrasonic)

Frequently Asked Questions

What is the purity of this product?

This product is supplied at ≥99% purity (chemical assay). Lot-specific values are stated on the Certificate of Analysis.

How should this product be stored?

Store at 2–8 °C, protected from light, desiccated. Keep the container tightly closed with desiccant — the material is moisture-sensitive.

How is this product shipped?

This product ships chilled on wet ice. Unpack on arrival and transfer it to the storage condition stated above.

What are the CAS number, molecular formula and molecular weight?

The CAS Number is 2348795-14-0, the molecular formula is C22H24N2O3, and the molecular weight is 364.44 g/mol.

What documentation is provided?

Available product documentation, including Certificates of Analysis (COA), Safety Data Sheets (SDS), and specification sheets, is shown in the product document area. Document availability and access follow the current site policy.